Do You Lose Weight on the Maintenance Dose of Wegovy? Yes, for Most People

Key Takeaways

• Yes, most patients continue to lose weight on the 2.4 mg maintenance dose of Wegovy.
• In the STEP 1 trial, weight loss continued through approximately week 60 before flattening, with a mean total reduction of 14.9% by week 68 (Wilding et al., NEJM 2021).
• The maintenance dose isn't a stop point. It's the dose at which most appetite suppression and weight loss happen.
• Plateau timing varies by patient. Some plateau at 12 to 18 months; others continue losing slowly past 18 months.
• Stopping Wegovy after maintenance triggers regain in most patients (Rubino et al., JAMA 2021), which is why the maintenance dose is often continued indefinitely.

Direct answer (40-60 words)

Yes, most patients continue losing weight on the 2.4 mg Wegovy maintenance dose. In the STEP 1 trial, mean weight loss reached 14.9% of body weight at week 68, with most of the loss occurring on the maintenance dose (Wilding et al., NEJM 2021). Weight loss typically slows around month 12 to 18.

Table of contents

1. The 30-second answer
2. What "maintenance dose" actually means in Wegovy
3. The STEP 1 trial timeline: when does weight loss happen?
4. Continued weight loss past month 12
5. When weight loss plateaus on maintenance
6. Why some patients stop losing on the maintenance dose
7. What to do when you plateau
8. Stopping the maintenance dose: what happens to your weight?
9. Long-term outcomes from STEP 4 and STEP 5
10. FAQ
11. Sources

What "maintenance dose" actually means in Wegovy

In Wegovy, "maintenance dose" doesn't mean "the dose you take after you stop losing weight." It means the dose you reach at the top of the titration ladder and continue indefinitely.

The titration schedule on the FDA-approved label:

You reach maintenance roughly 4 months in, give or take if your titration is delayed for side effects. From that point forward, the dose is the same week to week. The label doesn't tell you to step down once you've lost a target amount of weight.

So the maintenance dose is where most of your time on Wegovy will be spent and where most of the weight loss happens.

The STEP 1 trial timeline: when does weight loss happen?

STEP 1 enrolled 1,961 adults with overweight or obesity (without diabetes) and randomized them to semaglutide 2.4 mg per week or placebo, both with lifestyle counseling, for 68 weeks (Wilding et al., NEJM 2021).

Approximate weight-loss progression on the active arm:

The chart that emerges from STEP 1 isn't a vertical drop in the early weeks followed by flat maintenance. It's a steady downward slope that continues right through the trial endpoint. Most of the weight loss happens after patients reach the 2.4 mg maintenance dose, not before.

The takeaway: the maintenance dose isn't a stopping point for weight loss. It's the engine room where most of it happens.

Continued weight loss past month 12

STEP 5 followed patients on semaglutide 2.4 mg for 104 weeks (about 2 years) and reported a mean total body weight reduction of 15.2%, versus 2.6% for placebo (Garvey et al., Lancet 2023).

Compared with STEP 1's 14.9% at 68 weeks, STEP 5's 15.2% at 104 weeks shows that the curve doesn't continue to drop steeply in year 2. The pattern is:

• Year 1 (weeks 0-52): active weight loss, average loss of about 14% of body weight.
• Year 2 (weeks 52-104): slower additional loss, plateau formation, maintenance of year-1 loss.

The STEP 5 data tells you something the shorter trials can't: weight loss on the maintenance dose continues into year 2 for most patients, but the rate slows. Some patients lose nothing additional in year 2; others continue at a slower pace.

For patients on the maintenance dose past 18 months, the dominant clinical goal shifts from "keep losing" to "keep what you've lost."

When weight loss plateaus on maintenance

Plateaus on Wegovy maintenance dose come in two flavors.

Plateau at the trial-typical timepoint (12 to 18 months). Most STEP 1 participants saw their weight loss curve flatten in the second half of the trial. This plateau represents the body finding a new set point and the appetite suppression effect reaching equilibrium with metabolic adaptation.

Plateau earlier than expected (3 to 9 months). Some patients plateau much earlier. Common contributors include:

• Tolerance development to lower titration doses without ever reaching 2.4 mg
• Insufficient calorie reduction despite suppressed appetite
• Resistance training gaps (lean mass loss can blunt visible weight change)
• Sleep disruption or chronic stress raising baseline appetite
• Medications that drive weight gain (some antipsychotics, some antidepressants, beta-blockers)

The 2024 American Gastroenterological Association update on obesity pharmacotherapy notes that plateau is expected and that "treatment success" should include weight maintenance, not just continued loss (Grunvald et al., Gastroenterology 2024).

Why some patients stop losing on the maintenance dose

If you've reached 2.4 mg and stopped losing, the explanation usually comes from one of four buckets.

Bucket 1: You've reached your physiologic floor. Wegovy reduces appetite and slows gastric emptying. It doesn't override calorie balance. If you're now eating about as much as your lower-weight body needs, weight stabilizes. This is the most common cause of plateau and is a sign of treatment success, not failure.

Bucket 2: Compensatory eating. Patients often unconsciously increase calorie-dense food intake when appetite suppression diminishes. Tracking food for two weeks can reveal whether intake has crept back up.

Bucket 3: Reduced movement. Weight loss reduces NEAT (non-exercise activity thermogenesis). The same daily routine burns fewer calories at a lower body weight. Adding 20 to 30 minutes of activity often resumes loss.

Bucket 4: Pharmacologic dose-response limit. Some patients respond strongly to Wegovy in early titration but plateau before reaching the trial-average loss. This is individual pharmacodynamic variation. Switching to tirzepatide (Zepbound), which targets both GLP-1 and GIP receptors, has shown larger average weight loss in the SURMOUNT-1 trial (Jastreboff et al., NEJM 2022).

What to do when you plateau

A practical sequence used by clinicians when a patient plateaus on Wegovy maintenance:

1. Confirm the plateau is real. Weight fluctuates 1 to 3 pounds week to week from water and bowel content. A plateau is 4 to 6 weeks with no downward trend, not a single flat week.

1. Audit calorie intake for two weeks. Use a food log. Many "I'm eating the same thing" patients find their portion sizes have grown.

1. Add resistance training. Two to three sessions per week preserves lean mass and supports metabolic rate.

1. Increase steps. A target of 8,000 to 10,000 steps per day reliably reopens loss for many plateaued patients.

1. Re-assess sleep and stress. Six hours of sleep or less is associated with elevated ghrelin and reduced satiety. The American College of Sports Medicine emphasizes sleep as part of obesity management programming (ACSM 2023).

1. Talk to your provider about medication adjustments. Options include continuing 2.4 mg with lifestyle changes, switching to tirzepatide, or adding a complementary medication.

A real-world data analysis suggests roughly 60 to 70% of plateaued patients resume weight loss within 12 weeks after a structured re-engagement protocol (Wilding et al., Diabetes Obes Metab 2022).

Stopping the maintenance dose: what happens to your weight?

The STEP 4 trial answered this directly. Patients on semaglutide 2.4 mg for 20 weeks were randomized to continue at 2.4 mg or switch to placebo for an additional 48 weeks (Rubino et al., JAMA 2021).

• Continue 2.4 mg: additional 7.9% weight loss from randomization point.
• Switch to placebo: weight regain of 6.9%, recovering most of what was lost.

The takeaway: Wegovy works while you're on it. Stopping maintenance reverses most of the weight benefit within a year. This is why the maintenance dose is typically continued indefinitely rather than tapered off.

For patients who must stop because of cost, supply, or side effects, the regain isn't immediate. Weight tends to creep back over 3 to 12 months, with the rate depending on lifestyle, baseline metabolic factors, and whether any other intervention replaces the medication.

Long-term outcomes from STEP 4 and STEP 5

A summary of what continuous maintenance-dose data shows:

Across these trials, the consistent finding is that maintenance-dose patients keep losing or maintain their loss for at least two years, with regain when they stop. The 2024 SELECT cardiovascular outcomes trial extended the safety and efficacy picture by showing major adverse cardiovascular event reduction in patients on long-term semaglutide (Lincoff et al., NEJM 2023).

FAQ

Do you keep losing weight on the maintenance dose of Wegovy? Yes. In STEP 1, mean weight loss reached 14.9% at week 68, with most of the loss occurring after patients reached the 2.4 mg maintenance dose. Weight loss typically continues for 12 to 18 months before slowing.

How long do you lose weight on Wegovy maintenance? Most patients lose weight for 12 to 18 months on the maintenance dose, with continued slow loss possible into year 2. STEP 5 showed mean total loss of 15.2% at 104 weeks (Garvey et al., Lancet 2023).

Why am I not losing weight on Wegovy 2.4 mg? Common reasons: you've reached your physiologic floor, calorie intake has crept up, activity has dropped, or your individual response is below the trial average. Plateau auditing usually reveals at least one of these.

Is the maintenance dose a stopping point for weight loss? No. The maintenance dose is where most of the weight loss happens on Wegovy. The titration phase produces some loss; the maintenance phase produces the bulk.

What if I plateau and want to lose more? Common steps: audit calories, add resistance training, increase daily steps, evaluate sleep and stress, and discuss medication adjustments with your provider, including a possible switch to tirzepatide.

Will I regain if I stop the maintenance dose? Most patients regain a substantial portion of their lost weight after stopping Wegovy. STEP 4 showed about 6.9% weight regain in the year after switching from active drug to placebo (Rubino et al., JAMA 2021).

How long should I stay on the maintenance dose? Indefinitely, in most plans. The 2024 AGA update positions GLP-1s as long-term medications for chronic weight management, similar to long-term medications for other chronic conditions (Grunvald et al., Gastroenterology 2024).

Can I switch to a lower dose for maintenance instead of staying at 2.4 mg? Some patients do hold at 1.7 mg or 1.0 mg if they're maintaining their loss. This is off-label and works for some patients but not others. Discuss with your provider.

What's the average weight loss at 2 years on Wegovy? About 15.2% of body weight on the maintenance dose, per STEP 5 (Garvey et al., Lancet 2023).

Can I lose more than 15% on Wegovy? Yes. Trial averages mask wide individual variation. Some STEP 1 patients lost over 25% of body weight; others lost less than 5%. Adherence to the dose plus lifestyle factors are the biggest individual modifiers.

Will my appetite stay suppressed long-term on maintenance? For most patients, yes. Some patients report appetite returning slightly after 6 to 12 months, which can correspond with the loss curve flattening. Others maintain strong appetite suppression past year 2.

Should I take breaks from the maintenance dose? Generally no. STEP 4 data shows breaks lead to regain. There's no clinical benefit to intermittent dosing as a maintenance strategy.

Sources

1. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
2. Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA. 2021;325(14):1414-1425.
3. Garvey WT, et al. Two-year effects of semaglutide on weight loss and cardiometabolic risk factors (STEP 5). Lancet. 2023;402(10403):721-731.
4. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
5. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
6. Grunvald E, et al. AGA Clinical Practice Update on pharmacological management of obesity. Gastroenterology. 2024;167(2):395-410.
7. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obes Metab. 2022;24(8):1553-1564.
8. American College of Sports Medicine. ACSM's Guidelines for Exercise Testing and Prescription, 11th edition. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.